Pharmaceutical Technology

FEBRUARY 8, 2024

In recognition of its 30th anniversary, the International Gaucher Alliance (IGA) unveiled a visionary five-year strategic plan extending to 2029.

52

52

STAT

SEPTEMBER 18, 2024

A House committee on Wednesday passed a bill to renew a program aimed at aiding development of drugs for rare diseases in children , putting it in a better position to be added to government funding legislation.    The pediatric rare disease priority review voucher program is set to end on Sept.

185

185

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Pancreatic Cancer.

52

52

Express Pharma

OCTOBER 10, 2023

Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio, with anticipated sales surpassing $7 billion and a 48 per cent market share of small molecules in lung cancer treatment by 2029, according to GlobalData. It is anticipated to generate $361 million in sales for lung cancer treatment by 2029.

102

102

Express Pharma

APRIL 12, 2024

These were further analysed and shortlisted to ensure that there is entrepreneurial, scientific, innovation and investment capability on ground to see these succeed in the run up to the next general elections by 2029. Let me begin by giving you the headline first.

Online Pharmacies 96

Online Pharmacies Communication Diabetes 96

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Hepatocellular Carcinoma.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Bladder Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Solid Tumor.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Thymoma (Thymic Epithelial Tumor).

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

40

40

Express Pharma

SEPTEMBER 4, 2023

SB5 is set to become a leading biosimilar for this debilitating, chronic condition, with a global sales forecast of $832 million by 2029, according to GlobalData. The post Humira biosimilar to see $832 million in sales by 2029: GlobalData appeared first on Express Pharma.

Biosimilars 52

Biosimilars 52

Pharma Times

MAY 28, 2024

The MRC BRC and the MDU will use the funding and cutting-edge research to improve public health until March 2029

115

115

STAT

OCTOBER 31, 2023

Later, Amgen reworked old patent applications and, by doing so, succeeded in extending patent protection for the medicine from 2019 until 2029, according to an analysis by the advocacy group. Continue to STAT+ to read the full story…

Drug Pricing 318

Drug Pricing 318

The Pharmacist

MAY 21, 2024

The commitment came as part of the Welsh Government’s Strategic Workforce Plan for Primary Care for 2024/25-2029/30, published last week. The plan also committed […] The post GP pharmacists in Wales to get structured induction programme appeared first on The Pharmacist.

Pharmacy Technician 136

Pharmacy Technician 136

Express Pharma

MARCH 15, 2024

per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029. per cent CAGR and a market size of $51 billion in 2029, nearly half of the GLP1 agonist market. billion annually by 2029.

Diabetes 105

Diabetes Compounding 105

Outsourcing Pharma

JUNE 27, 2024

The US Food and Drug Administration (FDA) has approved Verona Pharmaâs Ohtuvayre (ensifentrine), marking a significant milestone in the treatment of chronic obstructive pulmonary disease (COPD).

52

52

PharmaTech

AUGUST 21, 2024

This Behind the Headlines news roundup panel discussion covers news items such as the resurgence of mpox in Africa, “medical tourism” in India, Eli Lilly’s new Boston CGT facilities, and contract development and manufacturing organization (CDMO) projected growth rates for the 2023–2029 period, and the reasons behind them.

52

52

STAT

SEPTEMBER 19, 2024

House committee passed a  bill  to renew a program aimed at aiding development of drugs for rare diseases in children, putting it in a better position to be added to government funding legislation , STAT reports. The pediatric rare disease priority review voucher program is set to end on Sept.

Compounding 154

Compounding Compounding Pharmacies Packaging 154

Pharmaceutical Technology

JUNE 27, 2024

Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.

52

52

Pharmaceutical Technology

JUNE 24, 2024

The KRAS inhibitor, Krazati, is expected to generate $1.3bn in global sales in 2029, as per GlobalData’s analysis.

Labelling 52

Labelling 52

STAT

JUNE 25, 2024

The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.

270

270

Pharmaceutical Technology

JULY 31, 2023

According to GlobalData, it is projected that the market for hepatitis B treatments will experience a sharp increase over the next six years.

52

52

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement 98

Process Improvement Biosimilars Drug Development 98

Pharmaceutical Technology

SEPTEMBER 22, 2023

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

59

59

Pharmaceutical Commerce

JANUARY 5, 2024

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

AUGUST 31, 2023

Daiichi Sankyo and AstraZeneca’s blockbuster anti-cancer drug Enhertu could become a pan-tumour drug, with projected sales of $9.9bn by 2029.

52

52

Pharmaceutical Technology

OCTOBER 23, 2023

The Remicade biosimilar is forecasted to have sales of $2.3bn by 2029 as a subcutaneous form is approved for the US market.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

NOVEMBER 1, 2023

The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.

Biosimilars 52

Biosimilars 52

Express Pharma

JULY 10, 2024

billion in the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Canada) by 2029, with $375.3 million in sales in 2029. GlobalData forecasts that the ALS market will reach sales of approximately $1.3 million being contributed by 12 late-stage agents, including pridopidine.

108

108

Express Pharma

AUGUST 31, 2023

The global market for mRNA-based oncology therapies is expected to reach a record-breaking $2 billion by 2029. per cent share by 2029, according to GlobalData. per cent of the total mRNA therapy market by 2029. BioNTech, a German pharma company, is expected to lead the market with projected sales of $885 million and a 44.6

Immunity 105

Immunity Immunization Vaccines 105

Express Pharma

NOVEMBER 16, 2023

The global cell and gene therapy market is expected to reach $80 billion in 2029, with a high compound annual growth rate of 51.6 per cent between 2023 and 2029, according to GlobalData forecasts. The US FDA is currently considering approval of Casgevy for SCA. The limiting factor for widespread usage of this drug is its high cost.

Compounding 59

Compounding 59

Pharmaceutical Technology

JULY 20, 2023

By 2029, RSV drugs are forecast to surpass $9bn in sales, This surge can be attributed to recent developments in preventative measures.

40

40

Express Pharma

FEBRUARY 5, 2024

GlobalData analyst consensus forecast predicts that tarlatamab will rake in $781 million by 2029 and will establish itself as a market leader for SCLC treatment. Globaldata analyst consensus forecast predicts HPN-217 and -328 to reach global sales of $161 and $192 million, respectively, by 2029. “

Compounding 105

Compounding Drug Development 105

Express Pharma

DECEMBER 28, 2023

According to GlobalData estimates, the global CGT market is projected to reach $80 billion by 2029. Oncology is expected to continue its lead as the indication and area of major development for cell and gene therapies, accounting for 44 per cent of the CGT market by 2029.

Drug Development 105

Drug Development 105

Express Pharma

JULY 15, 2024

According to GlobalData’s Parkinson’s disease market forecast and analysis to 2029, SL-APO is set to experience sizable growth in the seven major markets (7MM*), with sales increasing from $1.5 million in 2029, registering a compound annual growth rate (CAGR) of 25.2 million in 2024 to $4.7 per cent during the period.

Compounding 97

Compounding Labelling 97